Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Breast 1

Conditions

Prostatic Neoplasms 4Breast Neoplasms 4Colonic Neoplasms 3Rectal Neoplasms 2Melanoma 2Leukemia, Myelomonocytic, Acute 2Leukemia, Myeloid, Acute 2Leukemia, Monocytic, Acute 2Leukemia, Megakaryoblastic, Acute 2Leukemia, Erythroblastic, Acute 2Leukemia, Eosinophilic, Acute 2Leukemia, Basophilic, Acute 2Leukemia 2Kidney Neoplasms 2Wilms Tumor 1Unspecified Childhood Solid Tumor, Protocol Specific 1Tuberous Sclerosis 1Thyroid Neoplasms 1Spinal Cord Neoplasms 1Sarcoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pheochromocytoma 1Pediatric Solid Tumor 1Paraganglioma 1Pancreatic Neoplasms 1Neoplastic Syndromes, Hereditary 1Neoplasms 1Neoplasm Metastasis 1Melanoma, Cutaneous Malignant 1Lymphangioleiomyomatosis 1

Interventions

Venlafaxine Hydrochloride 1Tamoxifen 1Sertraline 1Genetic Testing 1Gabapentin 1Escitalopram 1Citalopram 1Chromatography, High Pressure Liquid 1Chemotherapy, Adjuvant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Hot Flashes × Genetic Testing × Clear all
NCT00667121 2025-02-14

Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline

Mayo Clinic

Completed
88 enrolled
Breast

Breast Neoplasms, Depression, Hot Flashes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡